Clinical trial · Interventional
GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma
A Study of Gemcitabine, L- Asparaginase, Ifosfamide, Dexamethasone and Etoposide Chemotherapy Followed by ASCT for Newly Diagnosed Stage IV, Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type
NCT03154918CI-TRIAL-00030252unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is to explore the efficacy and safety of GLIDE regiment in patients with aggressive NK/T cell lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma, Extranodal NK-T-Cell | Nasal Type Extranodal NK/T-Cell Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| GLIDE | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- GLIDE
- description
- Treated with GLIDE regiment chemotherapy for 4 cycles.
- interventionNames
- Drug: GLIDE
Primary outcomes (1)
- measure
- PFS
- timeFrame
- 2 years after recruitment
- description
- 2-year progression free survival
Secondary outcomes (3)
- measure
- CR
- timeFrame
- 2 and 6 month after GLIDE, and 3 month after ASCT
- description
- complete remission
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: 1. diagnosis of ENKL defined by World Health Organization classification 2008; 2. age above 18 years; 3. Eastern Cooperative Oncology Group performance status of 0-3; 4. adequate organ function defined as: total bilirubin≤2 times the upper limit of normal; alanine aminotransferase and aspartate aminotransferase levels≤2.5 times the upper limit of normal; serum creatinine≤1.5 mg/dL; creatinine clearance ≥50 mL/minute and normal electrocardiogram results. Exclusion Criteria: 1. uncontrolled infection; 2. pregnant or lactating women; 3. contraindication to one of the trial drugs (eg. anaphylaxis to L-asparaginase); 4. any coexisting medical problems of sufficient severity to prevent full compliance with the study protocol
References
Publications (0)
Data not yet available
No reference posted for this study.